199 related articles for article (PubMed ID: 31203803)
1. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
[TBL] [Abstract][Full Text] [Related]
2. Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds.
He C; Preiss L; Wang B; Fu L; Wen H; Zhang X; Cui H; Meier T; Yin D
ChemMedChem; 2017 Jan; 12(2):106-119. PubMed ID: 27792278
[TBL] [Abstract][Full Text] [Related]
3. Design and Stereochemical Research (DFT, ECD and Crystal Structure) of Novel Bedaquiline Analogs as Potent Antituberculosis Agents.
Geng Y; Li L; Wu C; Chi Y; Li Z; Xu W; Sun T
Molecules; 2016 Jul; 21(7):. PubMed ID: 27384553
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline.
Blaser A; Sutherland HS; Tong AST; Choi PJ; Conole D; Franzblau SG; Cooper CB; Upton AM; Lotlikar M; Denny WA; Palmer BD
Bioorg Med Chem; 2019 Apr; 27(7):1283-1291. PubMed ID: 30792104
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles.
Sutherland HS; Tong AST; Choi PJ; Conole D; Blaser A; Franzblau SG; Cooper CB; Upton AM; Lotlikar MU; Denny WA; Palmer BD
Bioorg Med Chem; 2018 May; 26(8):1797-1809. PubMed ID: 29482950
[TBL] [Abstract][Full Text] [Related]
6. 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.
Sutherland HS; Tong AST; Choi PJ; Blaser A; Conole D; Franzblau SG; Lotlikar MU; Cooper CB; Upton AM; Denny WA; Palmer BD
Bioorg Med Chem; 2019 Apr; 27(7):1292-1307. PubMed ID: 30803745
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units.
Choi PJ; Sutherland HS; Tong AST; Blaser A; Franzblau SG; Cooper CB; Lotlikar MU; Upton AM; Guillemont J; Motte M; Queguiner L; Andries K; Van den Broeck W; Denny WA; Palmer BD
Bioorg Med Chem Lett; 2017 Dec; 27(23):5190-5196. PubMed ID: 29107541
[TBL] [Abstract][Full Text] [Related]
8. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
9. Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology.
Sutherland HS; Tong AST; Choi PJ; Blaser A; Franzblau SG; Cooper CB; Upton AM; Lotlikar M; Denny WA; Palmer BD
Bioorg Med Chem; 2020 Jan; 28(1):115213. PubMed ID: 31810890
[TBL] [Abstract][Full Text] [Related]
10. Synthetic approaches towards bedaquiline and its derivatives.
Calvert MB; Furkert DP; Cooper CB; Brimble MA
Bioorg Med Chem Lett; 2020 Jun; 30(12):127172. PubMed ID: 32291133
[TBL] [Abstract][Full Text] [Related]
11. One-Pot Synthesis of Novel Hydrazono-1,3-Thıazolıdın-4-One Derivatives as Anti-HIV and Anti-Tubercular Agents: Synthesıs, Bıologıcal Evaluatıon, Molecular Modelling and Admet Studıes.
Pasha MA; Mondal S; Panigrahi N; Shetye G; Ma R; Franzblau SG; Zheng YT; Murugesan S
Curr HIV Res; 2022; 20(3):255-271. PubMed ID: 35549861
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel triaryldimethylaminobutan-2-ol derivatives against Mycobacterium tuberculosis.
Liu P; Fan S; Wang B; Cao R; Wang X; Li S; Lu Y; Zhong W
Bioorg Chem; 2020 Sep; 102():104054. PubMed ID: 32663665
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876-A Less Toxic and More Potent Analogue of Bedaquiline.
Choi PJ; Conole D; Sutherland HS; Blaser A; Tong AST; Cooper CB; Upton AM; Palmer BD; Denny WA
Molecules; 2020 Mar; 25(6):. PubMed ID: 32245020
[TBL] [Abstract][Full Text] [Related]
14. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Salifu EY; Agoni C; Olotu FA; Soliman MES
Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
[TBL] [Abstract][Full Text] [Related]
15. Halting ionic shuttle to disrupt the synthetic machinery-Structural and molecular insights into the inhibitory roles of Bedaquiline towards Mycobacterium tuberculosis ATP synthase in the treatment of tuberculosis.
Salifu EY; Agoni C; Olotu FA; Dokurugu YM; Soliman MES
J Cell Biochem; 2019 Sep; 120(9):16108-16119. PubMed ID: 31125144
[TBL] [Abstract][Full Text] [Related]
16. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
[TBL] [Abstract][Full Text] [Related]
17. Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents.
Jain PP; Degani MS; Raju A; Ray M; Rajan MG
Bioorg Med Chem Lett; 2013 Nov; 23(22):6097-105. PubMed ID: 24095091
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
Patel RV; Riyaz SD; Park SW
Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
[TBL] [Abstract][Full Text] [Related]
19. Optimizing cardio, hepato and phospholipidosis toxicity of the Bedaquiline by chemoinformatics and molecular modelling approach.
Girase R; Ahmad I; Pawara R; Patel H
SAR QSAR Environ Res; 2022 Mar; 33(3):215-235. PubMed ID: 35225110
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Anti-tubercular Analogues of Bedaquiline with Modified A-, B- and C-Ring Subunits.
Barbaro L; Nagalingam G; Triccas JA; Tan L; West NP; Priebbenow DL; Baell JB
ChemMedChem; 2023 Jan; 18(1):e202200533. PubMed ID: 36259365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
